Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 5/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3397494 | 1.00 | CYP1A2 (0.43) | CYP1A2HTR6RAD52ADRA1AHRH1 | |
| SCHEMBL8185710 | 1.00 | CYP1A2 (0.43) | CYP1A2HTR6RAD52ADRA1AHRH1 | |
| SCHEMBL2957143 | 0.94 | CYP1A2 (0.50) | CYP1A2RAD52 | |
| SCHEMBL3393223 | 0.94 | CYP1A2 (0.50) | CYP1A2RAD52 | |
| SCHEMBL25565524 | 0.86 | RAD52 (0.37) | CYP1A2RAD52 | |
| SCHEMBL12786272 | 0.86 | CYP1A2 (0.50) | CYP1A2HTR6 | |
| SCHEMBL2760246 | 0.84 | CYP1A2 (0.59) | CYP1A2HTR6 | |
| SCHEMBL2760249 | 0.84 | CYP1A2 (0.59) | CYP1A2HTR6 | |
| SCHEMBL12568589 | 0.84 | CYP1A2 (0.53) | CYP1A2HTR6 | |
| SCHEMBL9927920 | 0.84 | CYP1A2 (0.53) | CYP1A2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | claimed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | claimed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | claimed |
| EP-1490367-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-29 | — | — | EP | claimed |
| WO-2003080610-A1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-10-02 | — | — | WO | claimed |
| US-7659395-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-02-09 | — | — | US | disclosed |
| US-7649092-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-19 | — | — | US | disclosed |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-09-11 | — | — | US | disclosed |
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-08-28 | — | — | US | disclosed |
| EP-1490367-B1 | IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7378420-B2 | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-05-27 | — | — | US | disclosed |
| US-7348339-B2 | 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent | GLAXO GROUP LIMITED (GB) | 2008-03-25 | — | — | US | disclosed |
| CN-101035783-A | Urea derivatives as calcium channel blockers | NEUROMED PHARMACEUTICALS LTD (CA) | 2007-09-12 | — | — | CN | disclosed |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2006-03-23 | — | — | US | disclosed |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-09-08 | — | — | US | disclosed |
| US-6156752-A | Optically active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC (US) | 2000-12-05 | — | — | US | disclosed |
| EP-0899261-A1 | Optical active 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 1999-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207633-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | CYP1A2 2924/4885HTR6 2582/4885RAD52 3822/4885 |
| US-20060063775-A1 | Urea derivatives as calcium channel blockers | ORAI1, ATP2A1, CACNA1B | CYP1A2 2924/4885HTR6 2582/4885RAD52 3822/4885 |
| US-20050197328-A1 | Imidazopyridine derivatives as kinase inhibitors | NR4A3, XDH, MAPK8 | CYP1A2 1579/4885HTR6 2281/4885RAD52 3429/4885 |
| US-20080221117-A1 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ORAI1, ATP2A1, CACNA1B | CYP1A2 2924/4885HTR6 2582/4885RAD52 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.